AB
RAPT

Amalgamated Bank’s RAPT Therapeutics RAPT Stock Holding History

Amalgamated Bank’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed – – 3026
2025
Q2 		$0 Sell
1
-113
-99% -$862 ﹤0.01% 3116
2025
Q1 		$1K Hold
114
– – ﹤0.01% 2926
2024
Q4 		$1K Hold
114
– – ﹤0.01% 2955
2024
Q3 		$2K Hold
114
– – ﹤0.01% 2943
2024
Q2 		$3K Hold
114
– – ﹤0.01% 2931
2024
Q1 		$8K Sell
114
-349
-75% -$48.5K ﹤0.01% 2539
2023
Q4 		$92K Sell
463
-34
-7% -$4.21K ﹤0.01% 2028
2023
Q3 		$66K Hold
497
– – ﹤0.01% 2138
2023
Q2 		$74K Buy
497
+38
+8% +$5.92K ﹤0.01% 2171
2023
Q1 		$67K Sell
459
-30
-6% -$6.07K ﹤0.01% 2188
2022
Q4 		$77K Hold
489
– – ﹤0.01% 2246
2022
Q3 		$94K Buy
489
+5
+1% +$946 ﹤0.01% 2175
2022
Q2 		$71K Buy
484
+50
+12% +$6.66K ﹤0.01% 2320
2022
Q1 		$76K Buy
+434
New +$82K ﹤0.01% 2301

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCM
Boone Capital Management Atlanta, Georgia $326M AUM 86.31% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Amalgamated Bank's RAPT Position: Q3 2025 in Review

Amalgamated Bank sold out of RAPT Therapeutics (RAPT) in Q3 2025, closing a stake of 1 share.

Amalgamated Bank first reported a position in RAPT in Q1 2022 and held it in 14 quarters. The position peaked at $94K in Q3 2022. 65 funds tracked by Wall St. Rank hold RAPT as of Q3 2025.

  • Amalgamated Bank reported no remaining RAPT Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Amalgamated Bank sold 1 RAPT Therapeutics share in Q3 2025.
  • Amalgamated Bank first reported a position in RAPT Therapeutics in Q1 2022 and held it in 14 quarters.
  • Amalgamated Bank's RAPT Therapeutics position peaked at $94K in Q3 2022.
  • 65 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2025.

Based on Amalgamated Bank's 13F filing for Q3 2025, filed 29 Oct 2025.